Literature DB >> 10217828

HIV-1 attachment: another look.

S Ugolini1, I Mondor, Q J Sattentau.   

Abstract

HIV-1 attachment to host cells is generally considered to take place via high-affinity binding between CD4 and gp120. However, the binding of virion-associated gp120 to cellular CD4 is often weak, and most cell types that are permissive for HIV-1 infection express little CD4. Thus, other interactions between the virion and the cell surface could dominate the attachment process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217828     DOI: 10.1016/s0966-842x(99)01474-2

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  86 in total

1.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface.

Authors:  J Cladera; I Martin; P O'Shea
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

3.  Expression of MHC class II in T cells is associated with increased HIV-1 expression.

Authors:  M Saifuddin; G T Spear; C Chang; K A Roebuck
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

4.  An Update on Vaginal Microbicides.

Authors:  Christine Mauck; Gustavo Doncel
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

5.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN.

Authors:  Cinzia Nobile; Arnaud Moris; Françoise Porrot; Nathalie Sol-Foulon; Olivier Schwartz
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 8.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets.

Authors:  Chawaree Chaipan; Elizabeth J Soilleux; Peter Simpson; Heike Hofmann; Thomas Gramberg; Andrea Marzi; Martina Geier; Elizabeth A Stewart; Jutta Eisemann; Alexander Steinkasserer; Katsue Suzuki-Inoue; Gemma L Fuller; Andrew C Pearce; Steve P Watson; James A Hoxie; Frederic Baribaud; Stefan Pöhlmann
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

10.  Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate.

Authors:  Arjun Raghuraman; Vaibhav Tiwari; Qian Zhao; Deepak Shukla; Asim K Debnath; Umesh R Desai
Journal:  Biomacromolecules       Date:  2007-04-17       Impact factor: 6.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.